Aurinia Pharmaceuticals Inc. AUPH
Updated: 16 Jun 2026
No signal published yet
We already track Aurinia Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Aurinia Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aurinia Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2024, Aurinia reported first-quarter net product revenue of $50.3 million, representing approximately 46% growth compared to the same period in 2023. The company also initiated a share repurchase program of up to $150 million following a strategic board review.
What Firelda Watch includes for Aurinia Pharmaceuticals Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Aurinia Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aurinia Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more